Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion recommending approval of its BTK inhibitor ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, rheumatoid arthritis and Crohn's disease, but its use for GCA is still pending ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...